These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9333066)

  • 21. [Diffusion of ceftriaxone in human bone tissue].
    Soudry B; Sirot J; Lopitaux R; Dumont C; Delisle JJ; Parenton M
    Pathol Biol (Paris); 1986 Sep; 34(7):859-62. PubMed ID: 3537931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.
    Korting HC; Schäfer-Korting M; Maass L; Klesel N; Mutschler E
    Antimicrob Agents Chemother; 1987 Nov; 31(11):1822-5. PubMed ID: 3435129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose cefodizime as infection prophylaxis in abdominal surgery: a prospective multicenter study.
    Thalhammer F; Traunmüller F; Böhming HJ; Depisch D; Ilias W; Hollenstein U; Salem G; Wayand W; Burgmann H; Breyer S
    Infection; 1998; 26(2):136-8. PubMed ID: 9561389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftriaxone and cefotaxime are equally effective in the treatment of neutropenic fever.
    Cornely OA; Salzberger B; Bethe U; Seifert H; Fätkenheuer G; Diehl V; Schrappe M
    Antibiot Chemother (1971); 2000; 50():37-46. PubMed ID: 10874453
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac.
    Joly V; Pangon B; Brion N; Vallois JM; Carbon C
    J Pharmacol Exp Ther; 1988 Aug; 246(2):695-700. PubMed ID: 3042958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-shot treatment of uncomplicated gonorrhoea with third-generation cephalosporins with differing serum half-life. Results of a controlled trial with ceftriaxone and cefotaxime.
    Korting HC; Abeck D
    Chemotherapy; 1989; 35(6):441-8. PubMed ID: 2515041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of long-acting cephalosporins in the treatment of lower respiratory tract infections.
    Lode H; Eller J; Raffenberg M; Mauch H
    Clin Microbiol Infect; 2000; 6 Suppl 3():87-9. PubMed ID: 11449664
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
    Hitt CM; Nightingale CH; Quintiliani R; Nicolau DP
    Am J Health Syst Pharm; 1997 Jul; 54(14):1614-8. PubMed ID: 9248605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein binding of ceftriaxone, cefoperazone, and ceftizoxime.
    Hamilton RA; Kowalsky SF; McCormick EM; Echols RM
    Clin Pharm; 1987 Jul; 6(7):567-9. PubMed ID: 3480089
    [No Abstract]   [Full Text] [Related]  

  • 30. Concentrations of ceftriaxone in prostate adenoma tissue.
    Adam D; Naber KG
    Chemotherapy; 1984; 30(1):1-6. PubMed ID: 6198127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans.
    Martin C; Viviand X; Alaya M; Lokiec F; Ennabli K; Said R; Pecking M
    Antimicrob Agents Chemother; 1996 Mar; 40(3):812-5. PubMed ID: 8851621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefodizime: effects of sub-inhibitory concentrations on adhesiveness and bacterial morphology of Staphylococcus aureus and Escherichia coli: comparison with cefotaxime and ceftriaxone.
    Braga PC; Dal Sasso M; Maci S
    J Antimicrob Chemother; 1997 Jan; 39(1):79-84. PubMed ID: 9044031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.
    Regamey C
    Chemotherapy; 1985; 31(2):85-94. PubMed ID: 3987394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.
    Murgia R; Marchetti F; Cinco M
    Antimicrob Agents Chemother; 1999 Dec; 43(12):3030-2. PubMed ID: 10582905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition kinetics and dosage regimen of ceftriaxone in crossbred calves (short communication).
    Johal B; Srivastava AK
    Acta Vet Hung; 1999; 47(2):243-8. PubMed ID: 10344084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. The Italian Multicentre Community-Acquired Pneumonia Group.
    De Palma M; Rocchi D; Canepa G; Peri A; Cantone V
    Clin Ther; 1995; 17(3):413-24. PubMed ID: 7585845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftriaxone bone penetration in patients with septic non-union of the tibia.
    Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G
    Int J Infect Dis; 2011 Jun; 15(6):e415-21. PubMed ID: 21497532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Serum and tissue levels of cefodizime in the pediatric patients].
    Matsuura K; Ogata T; Araki K; Kaneko A; Kawasaki H; Kobayashi M; Naoki I; Namikawa T; Andoh T; Yamamoto H
    Jpn J Antibiot; 1994 Aug; 47(8):1071-6. PubMed ID: 7933536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Placental passage of cefodizime].
    Berthelot G; Bornet M; Bergogne-Bérézin E; Ravina JH
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):699-701. PubMed ID: 3054750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.